Empowering Personalized Immunotherapy to Treat Cancer

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy.

Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.

Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.

By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.

Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic